GLP-1 receptor agonists and GLP-1 & weight loss sectors. The fund invests in growth and value stocks of companies operating across diversified market capitalization. The fund employs proprietary ...

As this share has grown, however, Novo shareholders should be aware that GLP-1 agonists have become an ... but as can be seen in the above chart they are relatively negligible compared to Ozempic ...

Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong ...

Unplanned pregnancies are still regularly being reported among people using glucagon-like peptide 1 receptor agonist (GLP-1 RA ... records and electronic chart information) and compared ...

Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.

The company's breakthroughs with glucagon-like peptide-1 (GLP-1) agonists gave birth to a host ... the trends depicted in the chart below suggest that now could be a great time to pounce on ...

Owning shares of pharmaceutical giant Eli Lilly (NYSE: LLY) has generally been a great idea over the past year. Lilly's ...

Speaking at The New York Times’s DealBook Summit, Eli Lilly’s chief executive and an obesity medicine specialist discussed ...

Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.

Mounjaro & Zepbound: Key Top-Line Drivers for Lilly Tirzepatide is a dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA ... as ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...